VYNE Therapeutics reported a net loss of $8.6 million for the first quarter of 2025, with total revenues of $0.2 million. The company continued to progress its Phase 2b trial for repibresib gel in vitiligo, with top-line results expected mid-2025, and anticipates a cash runway into the second half of 2026. However, its Phase 1b psoriasis trial for VYN202 was placed on clinical hold due to testicular toxicity observed in a non-clinical toxicology study.

VYNE Therapeutics reported second quarter 2024 financial results, highlighting the initiation of a Phase 2b trial of VYN201 in nonsegmental vitiligo and a Phase 1a trial of VYN202. The company's cash position is expected to fund key clinical milestones through the end of 2025.

VYNE Therapeutics reported a net loss of $6.2 million on revenues of $0.1 million for the first quarter of 2024. The company is advancing its VYN201 program towards a Phase 2b trial and received IND clearance for its VYN202 program.

VYNE Therapeutics reported its financial results for the fourth quarter and year ended December 31, 2023. The company had cash, cash equivalents, restricted cash and marketable securities of $93.3 million as of December 31, 2023, which it believes will be sufficient to fund operations through the end of 2025.

VYNE Therapeutics reported its Q3 2023 financial results, highlighting a transformative $88.2 million capital raise to fund BET inhibitor programs through 2025. The company is progressing with Phase 2b preparatory activities for VYN201 in nonsegmental vitiligo and is on track for VYN202 IND submission by year-end 2023.

VYNE Therapeutics reported a net loss of $10.1 million for the second quarter of 2023, compared to a net loss of $8.5 million for the same period in 2022. Revenues totaled $0.1 million for both quarters, consisting of royalty revenue. The company's cash and cash equivalents were $20.7 million as of June 30, 2023, which is expected to fund operations through the end of 2023.

VYNE Therapeutics reported revenues of $0.1 million and a net loss of $5.6 million for the first quarter ended March 31, 2023. The company is advancing its pipeline of novel, small molecule BET inhibitors for immuno-inflammatory conditions and expects topline 16-week data for VYN201 in Q3 2023.

VYNE Therapeutics reported its Q4 and year-end 2022 financial results, highlighting the progress of its VYN201 and VYN202 programs and the ongoing Phase 1b trial for vitiligo.

VYNE Therapeutics reported its third-quarter results, highlighting the progress of its InhiBETTM BET inhibitor platform with the anticipated enrollment of the first patient in the Phase 1a/b trial for VYN201. The company also made progress in the VYN202 program and continued to analyze the Phase 2a data for FMX114.

VYNE Therapeutics reported a net loss of $8.5 million for the second quarter of 2022, compared to a net loss of $19.9 million for the same period in 2021. Revenues for the quarter were $0.1 million, a decrease from $0.3 million in the prior year, primarily due to the sale of the MST Franchise. The company's cash and cash equivalents were $42.8 million as of June 30, 2022 and anticipates that it will be sufficient to fund its operations into the third quarter of 2023.

VYNE Therapeutics reported financial results for Q1 2022, highlighting progress with FMX114 and VYN201. The company reported positive Phase 1b data for FMX114 and promising preclinical data for VYN201. They also completed the divestiture of their topical minocycline franchise.

VYNE Therapeutics reported financial results for the fourth quarter and year ended December 31, 2021. The company focused on developing novel therapies for immuno-inflammatory conditions and completed the divestiture of their topical minocycline MST franchise.

VYNE Therapeutics reported revenues of $4.1 million for the third quarter ended September 30, 2021, compared to $3.3 million for the three months ended September 30, 2020.

VYNE Therapeutics reported increased revenues for Q4 2020, driven by the launch of new products and a license agreement. The company is advancing its pipeline with FCD105 in Phase 3 and planning a Phase 2a study for FMX114.

Menlo Therapeutics reported revenue of $11.7 million for the second quarter of 2020, driven by AMZEEQ product sales, a license agreement with Cutia, and royalty revenue for Finacea. The company experienced a net loss of $167.4 million, primarily due to goodwill impairment, in-process research and development impairment, and CSR remeasurement.

Menlo Therapeutics' Q1 2020 revenues totaled $1.8 million, primarily from AMZEEQ sales, marking the company's transition to a commercial entity. The company is awaiting FDA review of FMX103 with a PDUFA date of June 2nd.

Menlo Therapeutics reported a net loss of $21.5 million for the fourth quarter of 2019, compared to a net loss of $17.6 million for the same period in 2018. The company's shareholders approved the merger with Foamix, expected to close on or about March 9, 2020.